Analyst Conference Summaries

Biotechnology Investor Aids

ImmunoGen
IMGN

conference date: February 17, 2017 @ 5:00 AM Pacific Time

AML Therapies, Part 2: Agios and Immunogen [September 29, 2016 at Seeking Alpha]

ImmunoGen Oversold Despite Strong Pipeline [July 7, 2016 at Seeking Alpha]

2016
04/29/2016
08/04/2016
10/28/2016
02/17/2017

Immunogen (IMGN) is a clinical-stage biotechnology company specializing in ADC's (antibody-drug conjugates) for cancer and other diseases.

Immunogen web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 HNSN
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MDVN
 MYL.
 NVDA
 OPXA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2016 William P. Meyers